PUNE, India, July 18, 2017 /PRNewswire/ --
According to a new market research report "Biologics Safety Testing Market by Product (Instruments, Services, Kits & Reagents), Test (Endotoxin, Sterility Test, Cell Line Authentication, Bioburden), Application (Vaccine Development, Blood Products, Stem Cell Research) - Global Forecast to 2022", published by MarketsandMarkets™, the Biologics Safety Testing Market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% from 2017 to 2022.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 66 Market Data Tables and 35 Figures spread through 139 Pages and in-depth TOC on "Biologics Safety Testing Market"
http://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html Early buyers will receive 10% customization on this report
Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.
The kits & reagents segment is expected to dominate the market in 2017
On the basis of products and services, the Biologics Safety Testing Market is segmented into kits & reagents, services, and instruments. The kits & reagents segment accounted for the largest share of the products segment. This growth can be attributed to the regular and repeated purchase of kits & reagents as compared to instruments.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=34624144
By application, the vaccine and therapeutics development segment is expected to dominate the market in 2017
On the basis of applications, the Biologics Safety Testing Market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing, and stem cell research. The vaccine and therapeutics development segment holds the largest share in the market. The growth of this segment is primarily attributed to the increase in initiatives for immunization, increase company investment in vaccines development and the rising prevalence of diseases.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=34624144
Asia is expected to offer lucrative growth opportunities
By region, the global Biologics Safety Testing Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.
Some of the major players operating in the Biologics Safety Testing Market are Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).
Browse Related Reports
Pyrogen Testing Market by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), Test (In Vitro, Lal, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021
http://www.marketsandmarkets.com/Market-Reports/pyrogen-testing-market-255266155.html
Sterility Testing Market by Product (Instruments, Services, Kits and Reagents), Test (Membrane Filtration Sterility Testing, Direct Inoculation Sterility Testing), Application (Pharmaceutical & Biotechnology, Medical Devices) - Global Forecasts to 2021
http://www.marketsandmarkets.com/Market-Reports/sterility-testing-market-208866931.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: +1-888-600-6441 Email: [email protected]
Visit Our Blog@ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
SOURCE MarketsandMarkets
Advertisement
According to a new market research report "Biologics Safety Testing Market by Product (Instruments, Services, Kits & Reagents), Test (Endotoxin, Sterility Test, Cell Line Authentication, Bioburden), Application (Vaccine Development, Blood Products, Stem Cell Research) - Global Forecast to 2022", published by MarketsandMarkets™, the Biologics Safety Testing Market is expected to reach USD 4.90 Billion by 2022 from USD 2.75 Billion in 2017, at a CAGR of 12.2% from 2017 to 2022.
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 66 Market Data Tables and 35 Figures spread through 139 Pages and in-depth TOC on "Biologics Safety Testing Market"
http://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html Early buyers will receive 10% customization on this report
Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.
The kits & reagents segment is expected to dominate the market in 2017
On the basis of products and services, the Biologics Safety Testing Market is segmented into kits & reagents, services, and instruments. The kits & reagents segment accounted for the largest share of the products segment. This growth can be attributed to the regular and repeated purchase of kits & reagents as compared to instruments.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=34624144
By application, the vaccine and therapeutics development segment is expected to dominate the market in 2017
On the basis of applications, the Biologics Safety Testing Market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing, and stem cell research. The vaccine and therapeutics development segment holds the largest share in the market. The growth of this segment is primarily attributed to the increase in initiatives for immunization, increase company investment in vaccines development and the rising prevalence of diseases.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=34624144
Asia is expected to offer lucrative growth opportunities
By region, the global Biologics Safety Testing Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.
Some of the major players operating in the Biologics Safety Testing Market are Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).
Browse Related Reports
Pyrogen Testing Market by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), Test (In Vitro, Lal, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021
http://www.marketsandmarkets.com/Market-Reports/pyrogen-testing-market-255266155.html
Sterility Testing Market by Product (Instruments, Services, Kits and Reagents), Test (Membrane Filtration Sterility Testing, Direct Inoculation Sterility Testing), Application (Pharmaceutical & Biotechnology, Medical Devices) - Global Forecasts to 2021
http://www.marketsandmarkets.com/Market-Reports/sterility-testing-market-208866931.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: +1-888-600-6441 Email: [email protected]
Visit Our Blog@ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
SOURCE MarketsandMarkets
